Prothena Corporation plc (PRTA)

NASDAQ: PRTA · IEX Real-Time Price · USD
24.77
-0.39 (-1.55%)
At close: Mar 28, 2024, 4:00 PM
24.74
-0.03 (-0.12%)
After-hours: Mar 28, 2024, 5:47 PM EDT

Company Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.

The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis.

Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.

The company was incorporated in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc
Prothena Corporation logo
Country Ireland
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 173
CEO Dr. Gene G. Kinney Ph.D.

Contact Details

Address:
77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands
Dublin 2, L2 D02 VK60
Ireland
Phone 011-353-1-236-2500
Website prothena.com

Stock Details

Ticker Symbol PRTA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001559053
CUSIP Number G72800108
ISIN Number IE00B91XRN20
SIC Code 2834

Key Executives

Name Position
Dr. Gene G. Kinney Ph.D. President, Chief Executive Officer and Director
Tran B. Nguyen M.B.A. Chief Financial Officer and Chief Strategy Officer
Brandon S. Smith Chief Operating Officer
Carol D. Karp Chief Regulatory Officer
Dr. Hideki Garren M.D., Ph.D. Chief Medical Officer
Dr. Wagner M. Zago Chief Scientific Officer
Mark C. Johnson C.F.A. Vice President of Investor Relations
Michael J. Malecek Chief Legal Officer and Company Secretary
David A. Ford Chief People Officer

Latest SEC Filings

Date Type Title
Feb 22, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 22, 2024 10-K Annual Report
Feb 21, 2024 8-K Current Report
Feb 15, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals